Discontinued — last reported Q3 '24
Business Segments · Litigation expense
Innovative Medicine — Litigation expense
Johnson & Johnson Innovative Medicine — Litigation expense increased by 1500.0% to $400.00M in Q3 2024 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2021
Last reportedQ3 2024Oct 22, 2025
Rolls up toLitigation Settlement Expense
How to read this metric
An increase represents heightened legal risk or unfavorable outcomes in litigation, negatively impacting profitability.
Detailed definition
This metric tracks the costs associated with legal proceedings, settlements, and potential liabilities specifically rela...
Peer comparison
Commonly disclosed by large pharmaceutical companies facing product liability or patent litigation.
Metric ID:
jnj_segment_innovative_medicine_litigation_expenseHistorical Data
8 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|
| Value | $150.00M | $150.00M | $150.00M | $25.00M | $25.00M | $25.00M | $25.00M | $400.00M |
| QoQ Change | — | +0.0% | +0.0% | -83.3% | +0.0% | +0.0% | +0.0% | >999% |
| YoY Change | — | — | — | — | -83.3% | -83.3% | -83.3% | — |
Range$25.00M – $400.00M
CAGR+75.2%
Avg YoY Growth-83.3%
Median YoY Growth-83.3%
Current Streak4 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — litigation expense?
- Johnson & Johnson (JNJ) reported innovative medicine — litigation expense of $400.00M in Q3 2024.
- What does innovative medicine — litigation expense mean?
- Legal costs and settlement provisions related to the pharmaceutical business unit.